Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

  • End date
    Dec 23, 2023
  • participants needed
  • sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
Updated on 23 July 2021


In this prospective, randomized, open-label, parallel group trial, the safety and efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with basal insulin once or twice daily plus pre-prandial insulin after 16 weeks of treatment in patients with type 1 diabetes. This trial will enable assessment of the clinically relevant endpoint of a change in HbA1c and Time in Range (TIR).


The objective of the current study is to investigate the efficacy and safety of IDegAsp twice daily compared to basal insulin once or twice daily plus pre-prandial insulin for 16 weeks in patients with type 1 diabetes mellitus. The primary endpoint in this study is the change from baseline in HbA1c. Patients with type 1 diabetes who meet the entry criteria are planned for inclusion in this trial. Approximately 40 patients will be enrolled in the study. Patients who qualify will be randomized to IDegAsp group or basal plus pre-prandial insulin group. Duration of treatment includes 2-week screening period, 16-week treatment observation period and 1-week follow-up.

Condition Glycosylated hemoglobin, glycosylated haemoglobin, hba1c, hemoglobin a1c, Time in Range, Type 1 Diabetes Mellitus With Diabetic Gastroparesis
Treatment insulin degludec/insulin aspart (IDegAsp), basal insulin plus pre-prandial insulin
Clinical Study IdentifierNCT04965051
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on23 July 2021


Yes No Not Sure

Inclusion Criteria

Patients 18 and 75 years with type 1 diabetes
Diagnosed as T1DM 12 months before enrollment in the study
HbA1c 7.0 to 10.0%
Receipt of basal plus pre-prandial insulin and/or oral anti-diabetic agents 12 weeks before enrollment in the study
BMI 35kg / m2

Exclusion Criteria

Patients with any of the following conditions will be excluded
Pregnant or lactating women
Severe hypoglycemia within one month
Myocardial infarction, stroke or other severe cardiovascular events within 6 months prior to informed consent
Receipt of Sulfonylureas, Meglitinides derivatives, Thiazolidinediones, Dpp-4 inhibitors or GLP-1 agonists within 3 months prior to informed consent
Current treatment with systemic steroids or immunosuppressive agents, or have immunologic deficiency disease at time of informed consent
Severe mental instability, or alcohol abuse, or drug abuse
Cancer within 5 years prior to informed consent
Pancreatitis of severe infectious diseases within 1 months prior to informed consent
Known hypersensitivity or allergy to the insulin
Renal impairment (CKD-EPI eGFR<60ml/min)
Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined
Participation in another trial within 2 months prior to informed consent
Patients that investigators believe may fail to complete the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note